Other languages Compugen Ltd.

Equities

CGEN

IL0010852080

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
2.17 ^USD	-0.91%		-11.07%	+9.60%

May. 30	Compugen Ltd. to Receive Milestone Payment from Astrazeneca Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	CI
May. 20	Truist Securities Trims Price Target on Compugen to $4 From $5, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	May. 30
Compugen Ltd. to Receive Milestone Payment from Astrazeneca Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	May. 30
Truist Securities Trims Price Target on Compugen to $4 From $5, Maintains Buy Rating	May. 20
Compugen : Reports First Quarter 2024 Results	May. 20
Transcript : Compugen Ltd., Q1 2024 Earnings Call, May 20, 2024	May. 20
Earnings Flash (CGEN) COMPUGEN Reports Q1 Revenue $2.6M, vs. Street Est of $1.2M	May. 20
Compugen: Q1 Earnings Snapshot	May. 20
Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 20
Compugen Reports First Quarter 2024 Results	May. 20
Compugen : Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential	May. 16
Compugen Names David Silberman CFO	May. 15
Compugen Appoints David Silberman as Chief Financial Officer	May. 15
Compugen Ltd. Announces CFO Changes, Effective August 15, 2024	May. 15
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024	May. 06
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	Apr. 26
Compugen : To Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	Apr. 25
Compugen to Participate in Two Upcoming Investor Conferences	Apr. 03
Compugen : Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	Mar. 11
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	Mar. 11
Truist Securities Adjusts Price Target on Compugen to $5 From $4, Maintains Buy Rating	Mar. 08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Compugen Ltd.

Equities

CGEN

IL0010852080

Other languages

Filters